Welcome Message
After the grand success of DEMENTIA 2018, we welcome you back for the 13th World Congress on Dementia and Alzheimer’s Disease slated on September 16-17, 2019 at Paris, France.
This year we aim to incorporate each and every attended sector related to Dementia and Alzheimer’s Diseases with the refreshing theme of “Exploring the Challenges in the Era of Dementia Research and Care”
DEMENTIA 2019 is your best opportunity to reach the largest assemblage of participants from around the world on a single platform. The event will provide a huge opportunity to showcase your research and receive recognition and certificates signed by our World-class eminent organizing committee at this 2-days conference.
Join us to enhance your experiences on the theme of the conference and catalyze the future exchange of knowledge to develop and celebrate a new, DEMENTIA - FREE WORLD!
Let's meet and explore in the City of Lights, PARIS.
Regards,
Organizing Committee
Dementia 2019
About Conference
We take immense pleasure and honour to welcome all the participants across the world to attend the esteemed 13th World Congress on Dementia and Alzheimer’s Disease slated on September 16-17, 2019 at Paris, France.
Dementia is a broad category of brain diseases that cause a long term and often gradual decrease in the ability to think and remember that is great enough to affect a person's daily functioning.
Dementia conference is an international congress which expects more than 50 speakers and more than 100 participants from all across the world. Dementia 2019 will provide you with wonderful exposure to the latest research and technology developing in the field of Dementia and Alzheimer’s disease. This is the perfect stage to develop and nourish your research interest and participate in the scientific discussion with global scientists. Along with this, Dementia 2019 will help the participants develop an international academic and business network.
The main focus of Dementia 2019 will be on Alzheimer’s disease, Dementia, Imaging Techniques associated with Biomarkers, various animal models, Geriatrics and Cognitive Disorder, Pathophysiology, Care practice and Awareness, Current Trends and Awareness in Dementia and Alzheimer.
We welcome all the renowned and aspiring researchers, scientists and business delegates, who are significantly putting their effort to improve the life of the population with Dementia.
Reasons to attend:
-Meet eminent experts and personalities working in the field of Neuroscience and Neurology
-Enhance your knowledge
-Share your innovative ideas
-Worldwide Networking and Career Opportunities
This platform will give you an international stage to conduct demonstrations, workshops, and symposiums to showcase your services and products. Dementia 2019 will avail you a chance to distribute information and to meet potential national and international delegates. Participants can approach the invited scientists to explore the new product line possibility and exchange ideas of developing novel therapeutics or products. World-renowned speakers, the most recent researches, innovations, and novel updates in the field of Dementia are hallmarks of this Congress.
Target Audiences:
· Presidents
· Directors
· Neurologists
· Neuroscientists
· Neurosurgeons
· Neurology Professors
· Neurology Assistant and Associate Professors
· Post-doctorates and Doctorates
· Dementia Researchers
· Medical College and Hospitals
· Business Entrepreneurs
· Training Institutes
· Software developing companies
· Medical Devices Manufacturing Companies
· Data Management Companies
· Pharmaceutical industries and Biotech Company
· Dementia community, society and associations
· Other experts in Dementia and dementia care
Scientific Sessions
Dementia: An Underlying Disease- Dementia is a broad category of brain diseases that cause a long term and often gradual decrease in the ability to think and remember that is great enough to affect a person's daily functioning. Alzheimer’s disease is the most common type of disease which covers 50-70% cases. The common symptoms of Dementia include emotional constraints, problem in finding words, lack of motivation etc. The severity of Dementia increases with a person’s age. The other common types of diseases which include Dementia are Vascular dementia, Lewy body dementia and Frontotemporal dementia. Worldwide, with Dementia or Related disorders nearly 44 million people have suffered in 2015, past results showed 35.66 million population lived with Dementia worldwide in the year 2010, with numbers expected to nearly double every twenty years, to 65.7 million in 2030 and 115.4 million in 2050. In 2010, fifty-eight per cent of all population with dementia lived in countries with lower or moderate incomes, with this proportion anticipated to rise to 63% till 2030 and 71% by 2050. This condition is anticipated to double by 2030 and quite triple by 2050 to 115 million.
Vascular Dementia and Stroke
Mixed Dementia
Clinical Stages in Dementia progression
Signs and Symptoms of Dementia
Diagnosis of Dementia
Related Dementia Conferences | Dementia and Alzheimer Conferences | Dementia and Alzheimer’s Disease Congress | Neuroscience Event | Dementia and Alzheimer Event | Dementia and Alzheimer’s Disease Conferences | Neuroscience Conferences | Neurology | Dementia|
Related Conferences:
12th World Congress on Advances and Innovations in Dementia, September 17-18, 2018 Singapore; 12th International Conference on Vascular Dementia and Dementia, March 14-16, 2019, London, UK; 11th International Conference on Alzheimers Disease and Dementia, June 3-4, 2019, London, UK; 2nd International Conference on Dementia and Dementia Care, April 17-18, 2019 Toronto, Canada; 11th International Conference on Vascular Dementia, February 15-16, 2019 Amsterdam, Netherlands
Related Associations and Societies:
Dementia Society of America; Alzheimer's Disease International (ADI); Acoustic Neuroma Association; Aicardi Syndrome Foundation and Alliance for Aging Research; Alzheimer’s Association, Alzheimer’s and Related Disorders Society of India; ALS Association and ALS Therapy Development Institute; Alternating Hemiplegia of Childhood Foundation and Alzheimer’s Drug Discovery Foundation; Lewy Body Dementia Association; Dementia Association; Alzheimer Society of Canada; Alzheimer’s Society of Ireland; Alzheimer’s Research UK; Alzheimer Europe
Alzheimer's Disease- Alzheimer's disease is the most common category of Dementia. It is a chronic neurodegenerative disorder and caused by brain cell death. The symptoms of brain cell death are memory loss, disorientation and cognitive decline. The size of the brain shrinks and the nerve cells and attachments in the tissues progressively reduced, which cannot be diagnosed in the living brain affected by Alzheimer's disease, post-mortem/autopsy will always show tiny inclusions in the nerve tissues, called as plaques and tangles. Plaques are found between the dying cells in the brain - from the build-up of a protein called Beta-amyloid (amyloid plaques). The tangles exist in the brain neurons, from the disintegration of the second protein, called Tau. There are no existing treatments or preventive measures to stop or cure Alzheimer’s. Most patients with Alzheimer’s are above 65 years of age but 4-5% cases are of early onset Alzheimer’s.
Stages of Alzheimer’s
Diagnosis of Alzheimer's
Cholinergic and Amyloid Hypothesis in Alzheimer's
Genetics in Alzheimer's
Clinical Studies of Alzheimer’s
Advanced Tests and Treatments
Related Dementia Conferences | Dementia and Alzheimer Conferences | Dementia and Alzheimer’s Disease Congress | Neuroscience Event | Dementia and Alzheimer Event | Dementia and Alzheimer’s Disease Conferences | Neuroscience Conferences | Neurology | Dementia|
Related Conferences:
12th World Congress on Advances and Innovations in Dementia, September 17-18, 2018 Singapore; 12th International Conference on Vascular Dementia and Dementia, March 14-16, 2019, London, UK; 11th International Conference on Alzheimers Disease and Dementia, June 3-4, 2019, London, UK; 2nd International Conference on Dementia and Dementia Care, April 17-18, 2019 Toronto, Canada; 11th International Conference on Vascular Dementia, February 15-16, 2019 Amsterdam, Netherlands
Related Associations and Societies:
Dementia Society of America; Alzheimer's Disease International (ADI); Acoustic Neuroma Association; Aicardi Syndrome Foundation and Alliance for Aging Research; Alzheimer’s Association, Alzheimer’s and Related Disorders Society of India; ALS Association and ALS Therapy Development Institute; Alternating Hemiplegia of Childhood Foundation and Alzheimer’s Drug Discovery Foundation; Lewy Body Dementia Association; Dementia Association; Alzheimer Society of Canada; Alzheimer’s Society of Ireland; Alzheimer’s Research UK; Alzheimer Europe
Parkinson’s Disease- Parkinson's disease Dementia is a cognitive decline in thinking and reasoning that develops in the person diagnosed with Parkinson's disease at least a year earlier. Nearly one million people in the US are living with Parkinson's disease. The cause is unknown, and although there is presently no cure, there are treatment options such as medication and surgery to manage its symptoms. Hence this conference will provide a platform to discuss the problem.
Key risk factors of Parkinson’s Disease
Multiple System Atrophy (MSA)
Progressive Supranuclear palsy
Neuropsychiatry of Parkinson’s Disease
Neuropathophysiological Symptoms of Parkinson’s
Clinical Diagnosis of Parkinson’s Disease
Related Dementia Conferences | Dementia and Alzheimer Conferences | Dementia and Alzheimer’s Disease Congress | Neuroscience Event | Dementia and Alzheimer Event | Dementia and Alzheimer’s Disease Conferences | Neuroscience Conferences | Neurology | Dementia|
Related Conferences:
12th World Congress on Advances and Innovations in Dementia, September 17-18, 2018 Singapore; 12th International Conference on Vascular Dementia and Dementia, March 14-16, 2019, London, UK; 11th International Conference on Alzheimers Disease and Dementia, June 3-4, 2019, London, UK; 2nd International Conference on Dementia and Dementia Care, April 17-18, 2019 Toronto, Canada; 11th International Conference on Vascular Dementia, February 15-16, 2019 Amsterdam, Netherlands
Related Associations and Societies:
Dementia Society of America; Alzheimer's Disease International (ADI); Acoustic Neuroma Association; Aicardi Syndrome Foundation and Alliance for Aging Research; Alzheimer’s Association, Alzheimer’s and Related Disorders Society of India; ALS Association and ALS Therapy Development Institute; Alternating Hemiplegia of Childhood Foundation and Alzheimer’s Drug Discovery Foundation; Lewy Body Dementia Association; Dementia Association; Alzheimer Society of Canada; Alzheimer’s Society of Ireland; Alzheimer’s Research UK; Alzheimer Europe
Neurodegenerative Diseases- Neurodegeneration is the progressive loss of structure or function of neurons, including the death of the nerve cells. It can cause your brain and nerves to deteriorate over time. The neurological conditions in which the Dementia occurs include some disorders like Parkinson's disease, Normal Pressure Hydrocephalus, Huntington's disease, and Creutzfeldt-Jakob disease (CJD). These diseases mimic Dementia or have Dementia as a major sign in the disease. The genetic factors are responsible for the establishment of disorders like Parkinson’s disease, Down Syndrome, Creutzfeldt-Jakob disease, Normal Pressure Hydrocephalus. The other factors for Dementia include physical factors like head injuries and Traumatic brain injuries.
Normal Pressure Hydrocephalus
Down syndrome linked with Dementia
Multiple Sclerosis
Epilepsy and Convulsions
Clinical Manifestations
Cutting Edge Technologies in Prevention and Treatment
Related Dementia Conferences | Dementia and Alzheimer Conferences | Dementia and Alzheimer’s Disease Congress | Neuroscience Event | Dementia and Alzheimer Event | Dementia and Alzheimer’s Disease Conferences | Neuroscience Conferences | Neurology | Dementia|
Related Conferences:
12th World Congress on Advances and Innovations in Dementia, September 17-18, 2018 Singapore; 12th International Conference on Vascular Dementia and Dementia, March 14-16, 2019, London, UK; 11th International Conference on Alzheimers Disease and Dementia, June 3-4, 2019, London, UK; 2nd International Conference on Dementia and Dementia Care, April 17-18, 2019 Toronto, Canada; 11th International Conference on Vascular Dementia, February 15-16, 2019 Amsterdam, Netherlands
Related Associations and Societies:
Dementia Society of America; Alzheimer's Disease International (ADI); Acoustic Neuroma Association; Aicardi Syndrome Foundation and Alliance for Aging Research; Alzheimer’s Association, Alzheimer’s and Related Disorders Society of India; ALS Association and ALS Therapy Development Institute; Alternating Hemiplegia of Childhood Foundation and Alzheimer’s Drug Discovery Foundation; Lewy Body Dementia Association; Dementia Association; Alzheimer Society of Canada; Alzheimer’s Society of Ireland; Alzheimer’s Research UK; Alzheimer Europe
Vascular Dementia- Vascular dementia is the second most common type of Dementia after Alzheimer’s Disease. It is also called as Multi-Infarct Dementia (MID) and Vascular Intellectual Impedance (VCI), is caused by issues in the supply of blood to the mind, normally a progression of minor strokes. Dementia is a general term describing problems with reasoning, planning, judgment, memory and other thought processes caused by brain damage from impaired blood flow to your brain. People with dementia give dynamic subjective hindrance, intensely or sub-acutely as in mellow psychological debilitation, every now and again step-wise, after various cerebrovascular occasions (strokes). A few people may seem to enhance amongst occasions and decrease after more noiseless strokes. A quickly decaying condition may prompt demise from a stroke, coronary illness, or infection. Dementia can be caused by ischemic or haemorrhagic infarcts influencing numerous mind regions, including the foremost cerebral supply route domain, the parietal projections, or the cingulate gyrus.
Clinical Phenotype and Pathogenetic Mechanisms
Neuronal Dysfunction in Vascular Dementia
Clinical Diagnosis of Vascular Dementia
Advancements in the Treatments of Vascular Dementia
Related Dementia Conferences | Dementia and Alzheimer Conferences | Dementia and Alzheimer’s Disease Congress | Neuroscience Event | Dementia and Alzheimer Event | Dementia and Alzheimer’s Disease Conferences | Neuroscience Conferences | Neurology | Dementia|
Related Conferences:
12th World Congress on Advances and Innovations in Dementia, September 17-18, 2018 Singapore; 12th International Conference on Vascular Dementia and Dementia, March 14-16, 2019, London, UK; 11th International Conference on Alzheimers Disease and Dementia, June 3-4, 2019, London, UK; 2nd International Conference on Dementia and Dementia Care, April 17-18, 2019 Toronto, Canada; 11th International Conference on Vascular Dementia, February 15-16, 2019 Amsterdam, Netherlands
Related Associations and Societies:
Dementia Society of America; Alzheimer's Disease International (ADI); Acoustic Neuroma Association; Aicardi Syndrome Foundation and Alliance for Aging Research; Alzheimer’s Association, Alzheimer’s and Related Disorders Society of India; ALS Association and ALS Therapy Development Institute; Alternating Hemiplegia of Childhood Foundation and Alzheimer’s Drug Discovery Foundation; Lewy Body Dementia Association; Dementia Association; Alzheimer Society of Canada; Alzheimer’s Society of Ireland; Alzheimer’s Research UK; Alzheimer Europe
Traumatic Brain Injury- Traumatic brain injury (TBI) is unpredictable damage with a wide range of side effects and incapacities. The effect on a man and his or her family can demolish. The reason for this site is to teach and enable guardians and survivors of awful mind wounds. This site expects to facilitate the progress from stun and lose hope at the season of cerebrum damage to adapting and critical thinking. The side effects of mental wounds and the country's best awful cerebrum damage recovery focus and asset data.
Repercussions of Traumatic brain Injury
Cerebrum Damage
Preventive Measures
Diagnostic methods for Brain Injuries
Care and Treatment for Traumatic Brain Injuries
Related Dementia Conferences | Dementia and Alzheimer Conferences | Dementia and Alzheimer’s Disease Congress | Neuroscience Event | Dementia and Alzheimer Event | Dementia and Alzheimer’s Disease Conferences | Neuroscience Conferences | Neurology | Dementia|
Related Conferences:
12th World Congress on Advances and Innovations in Dementia, September 17-18, 2018 Singapore; 12th International Conference on Vascular Dementia and Dementia, March 14-16, 2019, London, UK; 11th International Conference on Alzheimer's Disease and Dementia, June 3-4, 2019, London, UK; 2nd International Conference on Dementia and Dementia Care, April 17-18, 2019 Toronto, Canada; 11th International Conference on Vascular Dementia, February 15-16, 2019 Amsterdam, Netherlands
Related Associations and Societies:
Dementia Society of America; Alzheimer's Disease International (ADI); Acoustic Neuroma Association; Aicardi Syndrome Foundation and Alliance for Aging Research; Alzheimer’s Association, Alzheimer’s and Related Disorders Society of India; ALS Association and ALS Therapy Development Institute; Alternating Hemiplegia of Childhood Foundation and Alzheimer’s Drug Discovery Foundation; Lewy Body Dementia Association; Dementia Association; Alzheimer Society of Canada; Alzheimer’s Society of Ireland; Alzheimer’s Research UK; Alzheimer Europe
Neuropharmacology- The action of a drug on the nervous system and the neural mechanisms through which they influence behaviour is studied in neuropharmacology. Studying these interactions will help the researchers in developing drugs to treat neurological disorders, psychological disorders, pain, addiction and other diseases. Drug development in Dementia and Alzheimer’s Disease is based on evolving pathophysiological theory. Disease-modifying approaches include the targeting of amyloid processing, aggregation of tau, insulin signalling, neuroinflammation and neurotransmitter dysfunction, with efforts thus far yielding abandoned hopes and ongoing promise. Reflecting its dominance on the pathophysiological stage the amyloid cascade is central to many of the emerging drug therapies. Rigorous clinical trials on Dementia drugs are continuing in the USA and UK under the guidance of Alzheimer's society and it is reported that there is very less participation of people. The most of drugs are in the second and third phases. New medications for Dementia being developed in 2014/2015, 31% were named symptoms modifying. Such Dementia meetings will help researchers to know target areas for Drug development in Dementia and work towards it and also Dementia conferences exhibit clinical trial medications and offer positivity to discover new approaches in curing Dementia.
Drug development in Dementia
Clinical Trials in Dementia
Vaccine development against Beta-Amyloid
Animal Models and Translational Medicines
Anticonvulsant Drugs for Treatment
Beta-Amyloid Polymerization and Inflammation Inhibitor
Related Dementia Conferences | Dementia and Alzheimer Conferences | Dementia and Alzheimer’s Disease Congress | Neuroscience Event | Dementia and Alzheimer Event | Dementia and Alzheimer’s Disease Conferences | Neuroscience Conferences | Neurology | Dementia|
Related Conferences:
12th World Congress on Advances and Innovations in Dementia, September 17-18, 2018 Singapore; 12th International Conference on Vascular Dementia and Dementia, March 14-16, 2019, London, UK; 11th International Conference on Alzheimer's Disease and Dementia, June 3-4, 2019, London, UK; 2nd International Conference on Dementia and Dementia Care, April 17-18, 2019 Toronto, Canada; 11th International Conference on Vascular Dementia, February 15-16, 2019 Amsterdam, Netherlands
Related Associations and Societies:
Dementia Society of America; Alzheimer's Disease International (ADI); Acoustic Neuroma Association; Aicardi Syndrome Foundation and Alliance for Aging Research; Alzheimer’s Association, Alzheimer’s and Related Disorders Society of India; ALS Association and ALS Therapy Development Institute; Alternating Hemiplegia of Childhood Foundation and Alzheimer’s Drug Discovery Foundation; Lewy Body Dementia Association; Dementia Association; Alzheimer Society of Canada; Alzheimer’s Society of Ireland; Alzheimer’s Research UK; Alzheimer Europe
Geriatrics Dementia and Cognitive Disorder- Geriatrics or geriatric medication may be a speciality that focuses on the health care of older people. It aims to push health by preventing and treating diseases and disabilities in older adults. there's no set age at that patients are also underneath the care of a specialist or geriatric MD; an MD United Nations agency makes a speciality of the care of older people. Rather, this call is set by the individual patient’s needs, and therefore the availability of a specialist. It is vital to notice the distinction between gerontology, the care of aged people, and geriatrics, that is that the study of the ageing method itself.
Cognitive disorders square measure a class of mental state disorders that primarily influence learning, memory, perception, and drawback determination, and embody blackout, dementia, and delirium. Whereas anxiety disorders, mood disorders, and psychotic disorders can even have an effect on psychological feature and memory functions, the DSM-IV-TR doesn't contemplate these psychological feature disorders, because the loss of cognitive function is not the primary (causal) symptom. Causes vary between the various sorts of disorders however most include damage to the memory parts of the brain. Treatments rely on however the disorder is caused. Medication and therapies square measure the foremost common treatments but, for a few sorts of disorders like amnesia, treatments will suppress the symptoms however there is presently no cure.
Related Dementia Conferences | Dementia and Alzheimer Conferences | Dementia and Alzheimer’s Disease Congress | Neuroscience Event | Dementia and Alzheimer Event | Dementia and Alzheimer’s Disease Conferences | Neuroscience Conferences | Neurology | Dementia|
Related Conferences:
12th World Congress on Advances and Innovations in Dementia, September 17-18, 2018 Singapore; 12th International Conference on Vascular Dementia and Dementia, March 14-16, 2019, London, UK; 11th International Conference on Alzheimer's Disease and Dementia, June 3-4, 2019, London, UK; 2nd International Conference on Dementia and Dementia Care, April 17-18, 2019 Toronto, Canada; 11th International Conference on Vascular Dementia, February 15-16, 2019 Amsterdam, Netherlands
Related Associations and Societies:
Dementia Society of America; Alzheimer's Disease International (ADI); Acoustic Neuroma Association; Aicardi Syndrome Foundation and Alliance for Aging Research; Alzheimer’s Association, Alzheimer’s and Related Disorders Society of India; ALS Association and ALS Therapy Development Institute; Alternating Hemiplegia of Childhood Foundation and Alzheimer’s Drug Discovery Foundation; Lewy Body Dementia Association; Dementia Association; Alzheimer Society of Canada; Alzheimer’s Society of Ireland; Alzheimer’s Research UK; Alzheimer Europe
Neuroepigenetics- Neuroepigenetics is the field in Neurobiology that replaces the conventional thoughts on heritable epigenetic mechanisms, which involves in histone and chromatin modification which results in the variable expression of genes in the CNS. The numerous Neuroepigenetic mechanisms have been involved in several neurological and neurodegenerative diseases for the regulation of various epigenetic mechanisms. All the mechanisms in epigenetics will have a biochemical characteristic such that it helps in the regulation process. The basic principle of Neuroepigenetics is that once DNA methylation patterns are established upon the genome in terminally differentiated cells, those modifications are permanent and essentially immutable. Other epigenetic molecular mechanisms are also in play in neurons. Some are ATP-dependent chromatin remodelling, genomic imprinting, SNF2 chromatin remodelling.
Genome-wide Analysis of DNA and RNA
Epigenetic Mechanisms
Biochemical Mechanisms
CNS Epigenome- Therapeutic Implications
Related Dementia Conferences | Dementia and Alzheimer Conferences | Dementia and Alzheimer’s Disease Congress | Neuroscience Event | Dementia and Alzheimer Event | Dementia and Alzheimer’s Disease Conferences | Neuroscience Conferences | Neurology | Dementia|
Related Conferences:
12th World Congress on Advances and Innovations in Dementia, September 17-18, 2018 Singapore; 12th International Conference on Vascular Dementia and Dementia, March 14-16, 2019, London, UK; 11th International Conference on Alzheimer's Disease and Dementia, June 3-4, 2019, London, UK; 2nd International Conference on Dementia and Dementia Care, April 17-18, 2019 Toronto, Canada; 11th International Conference on Vascular Dementia, February 15-16, 2019 Amsterdam, Netherlands
Related Associations and Societies:
Dementia Society of America; Alzheimer's Disease International (ADI); Acoustic Neuroma Association; Aicardi Syndrome Foundation and Alliance for Aging Research; Alzheimer’s Association, Alzheimer’s and Related Disorders Society of India; ALS Association and ALS Therapy Development Institute; Alternating Hemiplegia of Childhood Foundation and Alzheimer’s Drug Discovery Foundation; Lewy Body Dementia Association; Dementia Association; Alzheimer Society of Canada; Alzheimer’s Society of Ireland; Alzheimer’s Research UK; Alzheimer Europe
Role of Amyloid Protein in Alzheimer’s and Dementia- The amyloid plaques and neurofibrillary tangles formation are thought to contribute to the degradation of the neurons (nerve cells) in the brain and the subsequent symptoms of Alzheimer's disease.
Amyloid Plaques: One of the hallmarks of Alzheimer's disease is the accumulation of amyloid plaques between nerve cells (neurons) in the brain. Amyloid generally indicates protein fragments that the body produces normally. Beta-amyloid is a protein fragment from an amyloid precursor protein (APP). In a healthy brain, these protein fragments are broken down and get eliminated. In Alzheimer, the fragments get accumulated to form hard & insoluble plaques.
Neurofibrillary tangles are insoluble twisted fibres found inside the brain's cells, consisting primarily of a protein called tau, which forms a structure called a microtubule. Transport of nutrients and other important substances from one part of the nerve cell to another done by the help of microtubule. In Alzheimer's disease, the tau protein is abnormal and results in collapse of the microtubule structures.
This session includes Amyloid Protein and Alzheimer’s Disease, Amyloid beta metabolism in Alzheimer’s, Brain accumulation of toxic amyloid beta, Amyloid Plaques and Neurofibrillary Tangles, Amyloid Neuroimaging and biomarkers, Amyloidosis and Neurodegeneration, The amyloid hypothesis and potential treatments, Amyloid beta deposition, cognition and brain volume.
Beta-Amyloid metabolism in Alzheimer’s
Neurofibrillary Tangles
Amyloid Neuroimaging and Other Diagnostic Methods
Demyelinating Diseases
Potential Treatments
Related Dementia Conferences | Dementia and Alzheimer Conferences | Dementia and Alzheimer’s Disease Congress | Neuroscience Event | Dementia and Alzheimer Event | Dementia and Alzheimer’s Disease Conferences | Neuroscience Conferences | Neurology | Dementia|
Related Conferences:
12th World Congress on Advances and Innovations in Dementia, September 17-18, 2018 Singapore; 12th International Conference on Vascular Dementia and Dementia, March 14-16, 2019, London, UK; 11th International Conference on Alzheimer's Disease and Dementia, June 3-4, 2019, London, UK; 2nd International Conference on Dementia and Dementia Care, April 17-18, 2019 Toronto, Canada; 11th International Conference on Vascular Dementia, February 15-16, 2019 Amsterdam, Netherlands
Related Associations and Societies:
Dementia Society of America; Alzheimer's Disease International (ADI); Acoustic Neuroma Association; Aicardi Syndrome Foundation and Alliance for Aging Research; Alzheimer’s Association, Alzheimer’s and Related Disorders Society of India; ALS Association and ALS Therapy Development Institute; Alternating Hemiplegia of Childhood Foundation and Alzheimer’s Drug Discovery Foundation; Lewy Body Dementia Association; Dementia Association; Alzheimer Society of Canada; Alzheimer’s Society of Ireland; Alzheimer’s Research UK; Alzheimer Europe
Bioinformatics Approach for Dementia- Bioinformatics advent can be used to regulate and evaluate data from the current high-throughput research technologies and render means for novel discoveries in the field of neurodegenerative diseases. It is reported that there is very little published data on Epigenomics. It is said that the data are obtained from high throughput technologies in the screening of the human brain. These data intend the upcoming researchers to know and design their experiments. Data Mining plays an important role in the prediction of the disorder, where the actual data is compared with the real data and the results are interpreted. The Transcriptomics and Proteomics studies have also been carried out providing necessary solutions for the problems.
Proteomics in Dementia
Transcriptomics in Dementia
Data Mining Methods for the Diagnosis of Dementia
Gene ontology and Genome-wide screening Approach towards Dementia
Related Dementia Conferences | Dementia and Alzheimer Conferences | Dementia and Alzheimer’s Disease Congress | Neuroscience Event | Dementia and Alzheimer Event | Dementia and Alzheimer’s Disease Conferences | Neuroscience Conferences | Neurology | Dementia|
Related Conferences:
12th World Congress on Advances and Innovations in Dementia, September 17-18, 2018 Singapore; 12th International Conference on Vascular Dementia and Dementia, March 14-16, 2019, London, UK; 11th International Conference on Alzheimer's Disease and Dementia, June 3-4, 2019, London, UK; 2nd International Conference on Dementia and Dementia Care, April 17-18, 2019 Toronto, Canada; 11th International Conference on Vascular Dementia, February 15-16, 2019 Amsterdam, Netherlands
Related Associations and Societies:
Dementia Society of America; Alzheimer's Disease International (ADI); Acoustic Neuroma Association; Aicardi Syndrome Foundation and Alliance for Aging Research; Alzheimer’s Association, Alzheimer’s and Related Disorders Society of India; ALS Association and ALS Therapy Development Institute; Alternating Hemiplegia of Childhood Foundation and Alzheimer’s Drug Discovery Foundation; Lewy Body Dementia Association; Dementia Association; Alzheimer Society of Canada; Alzheimer’s Society of Ireland; Alzheimer’s Research UK; Alzheimer Europe
Recent Advancements in the Diagnosis of Dementia- The assessment of Dementia in needed to rule out similar symptoms showing to such diseases such as depression, delirium which is curable. It is necessary to provide time to Dementia patients to plan the future and make them literate about the possible effects in the future. There are various tests for diagnosing Dementia such as Mini-Mental State Examination (MMSE), Mental Score Test, Trail Making Test. MMSE test includes a series of exercises in which various problems are checked with memory, speech, ability to respond. A blood test is also done to check levels of vitamin B12 and Thyroid hormones, which may be responsible. Brain scans such as MRI and CT scans used for checking brain tumour and Strokes in Vascular Dementia. Neurology gatherings talked rigorously on Dementia Diagnosis and it is always misleading to different conditions like Parkinson’s' disease. Hence discovery and establishment of new methodologies and techniques for analysis are in the urge for the Dementia society for dependable diagnosis methods.
Brain MRI scan techniques
Neurophysiological Testing
Neuro imaging
Biomarkers for diagnosis
Mini mental state Examination (MMSE)
Geriatric Depression Scale
Mental Score Test
Related Dementia Conferences | Dementia and Alzheimer Conferences | Dementia and Alzheimer’s Disease Congress | Neuroscience Event | Dementia and Alzheimer Event | Dementia and Alzheimer’s Disease Conferences | Neuroscience Conferences | Neurology | Dementia|
Related Conferences:
12th World Congress on Advances and Innovations in Dementia, September 17-18, 2018 Singapore; 12th International Conference on Vascular Dementia and Dementia, March 14-16, 2019, London, UK; 11th International Conference on Alzheimer's Disease and Dementia, June 3-4, 2019, London, UK; 2nd International Conference on Dementia and Dementia Care, April 17-18, 2019 Toronto, Canada; 11th International Conference on Vascular Dementia, February 15-16, 2019 Amsterdam, Netherlands
Related Associations and Societies:
Dementia Society of America; Alzheimer's Disease International (ADI); Acoustic Neuroma Association; Aicardi Syndrome Foundation and Alliance for Aging Research; Alzheimer’s Association, Alzheimer’s and Related Disorders Society of India; ALS Association and ALS Therapy Development Institute; Alternating Hemiplegia of Childhood Foundation and Alzheimer’s Drug Discovery Foundation; Lewy Body Dementia Association; Dementia Association; Alzheimer Society of Canada; Alzheimer’s Society of Ireland; Alzheimer’s Research UK; Alzheimer Europe
Case Reports in Dementia- The goal of much of the research activity in dementia is to develop interventions for 'treatment' or even 'cure'. The classical bench to bedside paradigm has been disappointing in dementia. There is a long list of putative dementia treatment compounds with favourable pre-clinical and early phase trial data that have been neutral or even potentially harmful when assessed in phase III studies. Lewy body dementia is a common but frequently underdiagnosed cause of dementia often mistaken for the more familiar entity of Alzheimer disease. Clinically, the distinction is important because it can have profound implications for management. The diagnosis of Lewy body dementia has important implications. It is associated with a high incidence of neuroleptic sensitivity, necessitating great caution in the use of these common antipsychotic agents. Early studies indicate cholinesterase inhibitors can be beneficial for treating the hallucinations and behaviour disturbances that afflict these patients and might also improve cognition.
AIDS associated Dementia Case Report
Patients living in care
Epileptic seizures and Dementia
Hospice person with Cancer and Dementia
Related Dementia Conferences | Dementia and Alzheimer Conferences | Dementia and Alzheimer’s Disease Congress | Neuroscience Event | Dementia and Alzheimer Event | Dementia and Alzheimer’s Disease Conferences | Neuroscience Conferences | Neurology | Dementia|
Related Conferences:
12th World Congress on Advances and Innovations in Dementia, September 17-18, 2018 Singapore; 12th International Conference on Vascular Dementia and Dementia, March 14-16, 2019, London, UK; 11th International Conference on Alzheimer's Disease and Dementia, June 3-4, 2019, London, UK; 2nd International Conference on Dementia and Dementia Care, April 17-18, 2019 Toronto, Canada; 11th International Conference on Vascular Dementia, February 15-16, 2019 Amsterdam, Netherlands
Related Associations and Societies:
Dementia Society of America; Alzheimer's Disease International (ADI); Acoustic Neuroma Association; Aicardi Syndrome Foundation and Alliance for Aging Research; Alzheimer’s Association, Alzheimer’s and Related Disorders Society of India; ALS Association and ALS Therapy Development Institute; Alternating Hemiplegia of Childhood Foundation and Alzheimer’s Drug Discovery Foundation; Lewy Body Dementia Association; Dementia Association; Alzheimer Society of Canada; Alzheimer’s Society of Ireland; Alzheimer’s Research UK; Alzheimer Europe
Treatment Modalities for Dementia- Treatment modality is a method that is followed to treat a patient suffering from a disease condition. The treatment modalities have three main approaches, which includes medical, psychological and sociocultural approaches. The most important consideration is that, in practice, no single treatment is considered sufficient for the treatment of Dementia. By now the combination therapy which involves the use of two or more drugs proves to be efficient. The other treatment methods which involve stem cell therapy and gene therapy has now created the spotlight in the Dementia Treatment. Hence the advanced treatment methods can be discussed in the conference.
Combination Therapy
ImmunoTherapy
Adjunct Therapy
Lamotrigine Therapy
Animal-assisted Therapy
Related Dementia Conferences | Dementia and Alzheimer Conferences | Dementia and Alzheimer’s Disease Congress | Neuroscience Event | Dementia and Alzheimer Event | Dementia and Alzheimer’s Disease Conferences | Neuroscience Conferences | Neurology | Dementia|
Related Conferences:
12th World Congress on Advances and Innovations in Dementia, September 17-18, 2018 Singapore; 12th International Conference on Vascular Dementia and Dementia, March 14-16, 2019, London, UK; 11th International Conference on Alzheimer's Disease and Dementia, June 3-4, 2019, London, UK; 2nd International Conference on Dementia and Dementia Care, April 17-18, 2019 Toronto, Canada; 11th International Conference on Vascular Dementia, February 15-16, 2019 Amsterdam, Netherlands
Related Associations and Societies:
Dementia Society of America; Alzheimer's Disease International (ADI); Acoustic Neuroma Association; Aicardi Syndrome Foundation and Alliance for Aging Research; Alzheimer’s Association, Alzheimer’s and Related Disorders Society of India; ALS Association and ALS Therapy Development Institute; Alternating Hemiplegia of Childhood Foundation and Alzheimer’s Drug Discovery Foundation; Lewy Body Dementia Association; Dementia Association; Alzheimer Society of Canada; Alzheimer’s Society of Ireland; Alzheimer’s Research UK; Alzheimer Europe
Dementia Care, Practice and Awareness- Dementia is a predominant disorder that affects a greater number of people around the world. Diagnosis of the patient with Dementia frightens the person affected by the syndrome, their family members and caretakers. A better understanding of public awareness of Dementia aids more effective health and social policies. Dementia patients need assistance and full-time care as much as drugs. Some common care practices in Dementia are assistance in food and fluid consumption, pain management, social engagement ensuring safety and security of Dementia patients. The main aim of care practices is to ensure cut in hospitalization and psychotropic drugs. Understanding patient’s mood changes, particular behaviour, speech problems and help in rectifying them. Dementia patients need end of life care, so qualified nursing staff is needed. Few care practices which are used are indoor and outdoor activities, visual and audio stimulation, Art therapy. Care practices in Dementia have been critical to engage in International Dementia meetings. In order to evolve in Dementia care, world gathering and genuine talks on Dementia care are required. The Dementia conference discusses public awareness as well as care practices to achieve a higher rate of early diagnosis and to decrease the distress among the patient, family and caregivers.
Dementia Nursing
Psycho-Social Interventions
Cognitive Training
Dementia Management
Dementia Care Advances using Cloud Technology
Assistive Health Care
Related Dementia Conferences | Dementia and Alzheimer Conferences | Dementia and Alzheimer’s Disease Congress | Neuroscience Event | Dementia and Alzheimer Event | Dementia and Alzheimer’s Disease Conferences | Neuroscience Conferences | Neurology | Dementia|
Related Conferences: 12th World Congress on Advances and Innovations in Dementia, September 17-18, 2018 Singapore; 12th International Conference on Vascular Dementia and Dementia, March 14-16, 2019, London, UK; 11th International Conference on Alzheimer's Disease and Dementia, June 3-4, 2019, London, UK; 2nd International Conference on Dementia and Dementia Care, April 17-18, 2019 Toronto, Canada; 11th International Conference on Vascular Dementia, February 15-16, 2019 Amsterdam, Netherlands
Related Associations and Societies:
Dementia Society of America; Alzheimer's Disease International (ADI); Acoustic Neuroma Association; Aicardi Syndrome Foundation and Alliance for Aging Research; Alzheimer’s Association, Alzheimer’s and Related Disorders Society of India; ALS Association and ALS Therapy Development Institute; Alternating Hemiplegia of Childhood Foundation and Alzheimer’s Drug Discovery Foundation; Lewy Body Dementia Association; Dementia Association; Alzheimer Society of Canada; Alzheimer’s Society of Ireland; Alzheimer’s Research UK; Alzheimer Europe
Market Analysis
About 46 million people in the world have been estimated to be suffering from dementia by 2015 and it may be increased to 50 million (approx. data) by 2017.whereas in America, about 5.5 million people of all ages are estimated to be suffering from dementia. Among 5.5 million, It’s been calculated that the people under 65 are about 2, 00,000 sufferings with dementia which is referred by the term “younger onset dementia”. By 2020, the people above 65 with dementia are estimated at around 5.8 million. In America, Alzheimer's is accounted as the 6th leading cause of death. The cost of cumulative care for Alzheimer's patients is estimated to be $236 billion in 2016 and the global cost is estimated to be $605 billion which is equal to the 1% of the world gross product. US Scientists have found that at the age of 65, 1/6th of women have more tendencies to develop Alzheimer's disease compared to the man with a chance of 1 in 11. Dementia rates were high among the African-American women compared to that of the Asia-American women and same way is calculated in the case of men in the USA. However, based on the environmental risk factors, one can develop symptoms regardless of gender.
Goal of the world congress on Dementia 2019 is to furnish an outstanding program for exchange of ideas and interventions by the researchers and scientists who have been inventing the new pathways and novel intercultural methods for various treatments associated with dementia. We strive to make Dementia 2019 a success with your support and eminent talks about dementia and prospective care and research works on dementia. We assure you the world-class facilities and hospitality entirely during the conference.
The 35.6 million people with dementia across the world in 2010 are expected to be double by 2030 to about 65.7 million and nearly double by 2050 to 115.4 million. It is estimated that as many as 5.1 million people of the US are thriving with Alzheimer’s disease and it can be increased with the raising ages. There are currently 390,000 New York population with Alzheimer’s disease or related dementia and it is approximated to be doubled by 2025 nearly an increase of 18% especially to the people aged 65 and above. In New York alone, Medicaid for Alzheimer costs around $4.5 billion each year which is the highest cost recorded compared with other cities in the USA. It is estimated that nearly 1/3 of seniors who die each year have Alzheimer or a related Dementia and it is also estimated that there are about 1 million Alzheimer and Dementia unpaid caregivers.
The risk of dementia increases with the age and causes mainly due to the brain cell degeneration. Due to the dysfunction of blood vessels after degeneration, blood vessels are unable to receive the oxygen levels properly and hence due to the lack in the supply of oxygen, the brain cells are not able to work properly and thus the risk of memory occurs. Based on the physiological factors and genetic relocation the type of dementia varies from individual to individual but the most common disease is Alzheimer's which attacks 3/4th of dementia population. The risk of dementia is reaching heights in the developing countries and the USA stands in one of the top 5 countries in developing dementia and related diseases.
Market Analysis in Australia:
Dementia is the second leading cause of death of Australians contributing to 5.4% of all deaths in males and 10.6% of all deaths in females each year. In 2016 dementia became the leading cause of death among Australian females, surpassing heart disease which has been the leading cause of death for both males and females since the early 20th century. Females account for 64.4% of all dementia-related deaths. In 2018, there is an estimated 425,416 Australians living with dementia-191,367 (45%) males
234,049 (55%) females
Without a medical breakthrough, the number of people with dementia is expected to increase to 536,164 by 2025 and almost 1,100,890 by 2056. Currently, an estimated 250 people are joining the population with dementia each day. The number of new cases of dementia will increase to 318 people per day by 2025 and more than 650 people by 2056. Three in 10 people over the age of 85 and almost one in 10 people over 65 have dementia. In 2018, there are an estimated 26,443 people with younger onset dementia, expected to rise to 29,375 people by 2025 and 42,252 people by 2056. An average of 36 people died per day where dementia was the underlying cause of death in 2016. Of the 13,126 people that lost their lives, 8,447 were female. In 2018, dementia is estimated to cost Australia more than $15 billion. By 2025, the total cost of dementia is predicted to increase to more than $18.7 billion in today’s dollars, and by 2056, to more than $36.8 billion. Dementia is the single greatest cause of disability in older Australians (aged 65 years or older) and the third leading cause of disability burden overall. People with dementia account for 52% of all residents in residential aged care facilities. In 2015, the Federal Government provided an additional $200 million for dementia research over five years, significantly boosting funding for Australia’s dementia research sector to more than $60 million per annum. The Federal Government established the National Health and Medical Research Council’s National Institute of Dementia Research to ensure research in dementia is coordinated, funded and communicated. One of the pressing issues is to build capacity in the dementia research sector by supporting students and early career dementia researchers. The Dementia Australia Research Foundation, supported by donations from the public, plays a major role in this effort and funds a number of new and early career researchers through scholarships and project grants.
